SCHEMBL26020274

SCHEMBL26020274

COC(=O)c1cc(O[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)c2ccccc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 4/20 0.41
HPGD P15428 2/20 0.41
ABL1 P00519 1/20 0.41
TSHR P16473 1/20 0.40
LCK P06239 1/20 0.39
ALOX15 P16050 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GPR84 Q9NQS5 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.37
TNKS O95271 1/20 0.36
PDE5A O76074 1/20 0.36
KIF11 P52732 1/20 0.36
PSMD14 O00487 1/20 0.36
FTO Q9C0B1 1/20 0.36
CYP3A4 P08684 1/20 0.36
AMPD3 Q01432 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25877355 0.88 PLA2G2A (0.38) KDM4EALDH1A1HPGDABL1TSHR
SCHEMBL9576467 0.82 LMNA (0.50) KDM4EALDH1A1HPGDABL1TSHR
SCHEMBL29215297 0.81 TSHR (0.46) ALDH1A1TSHRMEN1KMT2AHSD17B10
SCHEMBL30311488 0.81 TSHR (0.46) ALDH1A1TSHRMEN1KMT2AHSD17B10
SCHEMBL5235828 0.79 TSHR (0.46) KDM4EALDH1A1HPGDABL1TSHR
SCHEMBL9043929 0.78 CYP19A1 (0.44) KDM4EALDH1A1HPGDABL1TSHR
SCHEMBL18288014 0.77 HPGD (0.53) KDM4EALDH1A1HPGDTSHRLCK
SCHEMBL31493128 0.77 HPGD (0.53) KDM4EALDH1A1HPGDTSHRLCK
SCHEMBL17137658 0.77 KDM4E (0.53) KDM4EALDH1A1HPGDNPSR1MEN1
SCHEMBL30497380 0.77 MPL (0.44) KDM4EALDH1A1HPGDTSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265105-A1 MACROCYCLIC 7-PYRAZOL-5-YL-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 JANSSEN PHARMACEUTICA NV (BE) 2023-08-24 US disclosed
US-20230265105-A1 MACROCYCLIC 7-PYRAZOL-5-YL-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 JANSSEN PHARMACEUTICA NV (BE) 2023-08-24 US disclosed
US-20230130109-A1 MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 JANSSEN PHARMACEUTICA NV (BE) 2023-04-27 US disclosed
US-20230130109-A1 MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 JANSSEN PHARMACEUTICA NV (BE) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265105-A1 MACROCYCLIC 7-PYRAZOL-5-YL-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 MCL1, BAK1, API5 KDM4E 1526/4885ALDH1A1 1173/4885HPGD 1388/4885
US-20230130109-A1 MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 MCL1, BCL2L1, BAK1 KDM4E 1710/4885ALDH1A1 1067/4885HPGD 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.